AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04026256
Drug: Denosumab
RxNorm normalized name: Denosumab
DrugBank: Denosumab (DB06643)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: denosumab subcutaneous injection
Trial: NCT00089141
Drug: mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given orally
Trial: NCT00534677
Drug: Terlipressin
RxNorm normalized name: Terlipressin
DrugBank: Terlipressin (DB02638)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg stat \& then 1 mg q6h iv and Placebo of Octreotide
Trial: NCT00534677
Drug: Octreotide
RxNorm normalized name: Octreotide
DrugBank: Octreotide (DB00104)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Octreotide 50mcg/hr infusion \& a placebo of Terlipressin
Trial: NCT03896737
Drug: Velcade Thalidomide Dexamethasone
RxNorm normalized name: Velcade
DrugBank: Thalidomide (DB01041)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: To compare Dara-VCd versus VTd as pre transplant induction and post transplant consolidation, both followed by a maintenance phase with Ixazomib alone or in combination with Daratumumab, in newly diagnosed Multiple Myeloma (MM) young patients eligible for autologous stem cell transplantation.
Trial: NCT00676130
Drug: trimethoprim-sulfamethoxazole
RxNorm normalized name: sulfamethoxazole / trimethoprim
DrugBank: Trimethoprim (DB00440)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weight-based dosing in capsule or suspension form according to the following scale:~15-19 kg (33-42 lbs): trimethoprim-sulfamethoxazole 40/200 mg four times daily~20-24 kg (42-53 lbs): trimethoprim-sulfamethoxazole 60/300 mg four times daily~25-29 kg (53-64 lbs): trimethoprim-sulfamethoxazole 72/360 mg four times daily~29-60 kg (64-132 lbs): trimethoprim-sulfamethoxazole 80/400 mg four times daily~60 kg (132 lbs): trimethoprim-sulfamethoxazole 80/400 mg four times daily~60-80 kg (132-176 lbs): trimethoprim-sulfamethoxazole 160/800 mg three times daily~\> 80 kg (176 lbs): trimethoprim-sulfamethoxazole 160/800 mg four times daily
Trial: NCT00676130
Drug: Cephalexin
RxNorm normalized name: Cephalexin
DrugBank: Cephalexin (DB00567)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weight-based dosing in capsule or suspension form according to the following scale:~15-19 kg (33-42 lbs): Cephalexin 300 mg four times daily~20-24 kg (42-53 lbs): Cephalexin 400 mg four times daily~25-29 kg (53-64 lbs): Cephalexin 500 mg four times daily~29-60 kg (64-132 lbs): Cephalexin 500 mg four times daily~60-80 kg (132-176 lbs): Cephalexin 1000 mg three times daily~\> 80 kg (176 lbs): Cephalexin 1000 mg four times daily
Trial: NCT00959101
Drug: repaglinide and metformin combination tablet
RxNorm normalized name: metformin and repaglinide
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Combination tablet of repaglinide (1.0 mg)/metformin (500 mg) given just prior to a standard normal breakfast
Trial: NCT00959101
Drug: repaglinide and metformin combination tablet
RxNorm normalized name: metformin and repaglinide
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Combination tablet of repaglinide (2.0 mg)/metformin (500 mg) given just prior to a standard normal breakfast
Trial: NCT00959101
Drug: repaglinide
RxNorm normalized name: Repaglinide
DrugBank: Repaglinide (DB00912)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Co-administration of metformin 500 mg tablet and repaglinide 2 mg tablet given just prior to a standard normal breakfast
Trial: NCT00877409
Drug: Benzoyl Peroxide 5% and Sulphur 2%
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The product will be applied topically forming a thin layer, 1 time a day (at night) throughout the area affected by lesions.
Trial: NCT00959101
Drug: metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Concomitant administration: Metformin 500 mg tablet and Repaglinide 2 mg tablet
Trial: NCT02991482
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pembrolizumab (MK-3475) is a potent and highly selective humanised monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2. This blockade enhances functional activity of the target lymphocytes to facilitate tumour regression and ultimately immune rejection.
Trial: NCT00877409
Drug: Vehicle of Acnase
RxNorm normalized name: OIL OF CAMPHOR
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The product will be applied topically forming a thin layer, 1 time a day (at night) throughout the area affected by lesions.
Trial: NCT02991482
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine replaces one of the building blocks of nucleic acids, in this case cytidine, during DNA replication. The process arrests tumour growth, as new nucleosides cannot be attached to the faulty nucleoside, resulting in apoptosis (cellular suicide).
Trial: NCT02991482
Drug: Vinorelbine
RxNorm normalized name: Vinorelbine
DrugBank: Vinorelbine (DB00361)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vinorelbine is a vinca alkaloid cytotoxic chemotherapy that is available in intravenous and oral preparations with EMA licenses in lung cancer and breast cancer. Vinorelbine blocks mitosis in phase G2-M, causing cell death in interphase or at the following mitosis.
Trial: NCT03580590
Drug: oral Diltiazem
RxNorm normalized name: diltiazem Oral Capsule
DrugBank: Diltiazem (DB00343)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Diltiazem, a calcium channel blocker reduced arteriolar tone and fall in blood pressure
Trial: NCT03580590
Drug: IV Tranexamic Acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid inhibits fibrinolysis, which reduces blood loss
Trial: NCT01887470
Drug: Full dose preparation
RxNorm normalized name: cranberry preparation
DrugBank: Cranberry (DB10631)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01887470
Drug: Split dose preparation
RxNorm normalized name: cranberry preparation
DrugBank: Cranberry (DB10631)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00019058
Drug: hydroxyurea
RxNorm normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00019058
Drug: pentoxifylline
RxNorm normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02833844
Drug: Evolocumab
RxNorm normalized name: Evolocumab
DrugBank: Evolocumab (DB09303)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dose of subcutaneous evolocumab QM
Trial: NCT01051544
Drug: FVIII Concentrates
RxNorm normalized name: factor VIII
DrugBank: Antihemophilic factor, human recombinant (DB00025)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be centrally randomized to receive a von Willebrand factor-free FVIII concentrate (recombinant or plasma-derived, monoclonally-purified). The choice of product brand will be based on physician / patients preferences.
Trial: NCT00065104
Drug: DHEA
RxNorm normalized name: DHEA
DrugBank: Prasterone (DB01708)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00775840
Drug: Candesartan
RxNorm normalized name: Candesartan
DrugBank: Candesartan (DB13919)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candesartan up to 32 mg, tablets, orally, once daily and ongoing angiotensin-converting enzyme inhibitor/beta-blocker therapy for up to 24 weeks.
Trial: NCT00402480
Drug: Hydroxyurea
RxNorm normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00508404
Drug: Panitumumab
RxNorm normalized name: Panitumumab
DrugBank: Panitumumab (DB01269)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Administered by intravenous infusion
Trial: NCT02543255
Drug: Abiraterone acetate with prednisone
RxNorm normalized name: Abiraterone Acetate
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Abiraterone acetate will be administered orally as a tablet at 1000 mg/day with prednisone (5 mg oral tablet, twice daily) for 24 weeks.
Trial: NCT02543255
Drug: Leuprolide
RxNorm normalized name: Leuprolide
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leuprolide will be administered by subcutaneous injection at 22.5 mg dose every 12 weeks for 24 weeks.
Trial: NCT02543255
Drug: Cabazitaxel with peg-filgrastim
RxNorm normalized name: peg-filgrastim
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Cabazitaxel will be administered in 6 cycles, with 20 mg/m2 per cycle and 3 weeks between cycles.
Trial: NCT01052272
Drug: Ramipril
RxNorm normalized name: Ramipril
DrugBank: Ramipril (DB00178)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The starting dose of Ramipril will be 2.5 mg once daily and rapidly titrated upward to 5 mg once daily after 5 days if systolic blood pressure is greater than 100 mmHg. After one month the patient will return to clinic for blood pressure check and will be titrated up to 10 mg once daily.
Trial: NCT01052272
Drug: Candesartan cilexetil
RxNorm normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The starting dose of Candesartan cilexetil will be 4 mg or 8 mg once daily and doubled every 2 weeks, if systolic blood pressure is greater than 100 mmHg, to a maximum dose of 32 mg once daily. After one month the patient will return to clinic for blood pressure check and will be titrated up to 32 mg once daily.
Trial: NCT01052272
Drug: Allopurinol
RxNorm normalized name: Allopurinol
DrugBank: Allopurinol (DB00437)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The starting dose of Allopurinol is 300 mg daily.
Trial: NCT00722865
Drug: Avastin
RxNorm normalized name: Avastin
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given intravenously along with standard chemotherapy (Adriamycin, Bleomycin, Vinblastine and Dacarbazine) on days 1 and 15 of a 28-day cycle for a total of 6 planned cycles.
Trial: NCT01757288
Drug: NAB-PACLITAXEL
RxNorm normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: nab-Paclitaxel 50 mg/m2 IV/30min/wk x6 wks
Trial: NCT01757288
Drug: PACLITAXEL
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01757288
Drug: NAB-PACLITAXEL
RxNorm normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: nab-Paclitaxel 40 mg/m2 IV/30min/wk x6 wks
Trial: NCT00308087
Drug: Sargramostim (Leukine)
RxNorm normalized name: Sargramostim
DrugBank: Sargramostim (DB00020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sargramostim 250 μg, administered subcutaneously (SC) 3 times weekly for 8 weeks, beginning at least 1 hour before the first dose of rituximab
Trial: NCT00308087
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Four doses of rituximab 375 mg/m2, administered intravenously (IV) once weekly for 4 weeks
Trial: NCT00630175
Drug: zolpidem-MR (modified release)
RxNorm normalized name: zolpidem Extended Release Oral Tablet
DrugBank: Zolpidem (DB00425)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00630175
Drug: zolpidem (SL800750)
DrugBank: Zolpidem (DB00425)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00135798
Drug: LADR Treatment
RxNorm normalized name: Ladropen
DrugBank: Cladribine (DB00242)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PEG-Intron (peginterferon alfa-2b (PEGIFN)) Redipen; Rebetol (ribavirin (RBV) United States Pharmacopeia (USP)) Capsules:~Treatment was initiated with PEGIFN 0.75 µg/kg/week and RBV 600 mg/day. Dose escalations were performed at weeks 1 (PEGIFN 1.5 µg/kg/week and RBV 800 mg/day), 2 (RBV 1.0 g/day), and 3 (RBV 1.2 g/day for patients who weighed more then 75 kg) based upon patient tolerance and weekly blood counts. Once a patient reached the target RBV dose of 1-1.2 g/day (approximately 10.6 to 13.2 mg/kg/day), no further increases in RBV dose were made. Subsequent doses of PEGIFN and RBV were adjusted based upon adverse events, patient tolerability, and blood counts. If the highest tolerated dose of PEGIFN was \<0.5 ug/kg, PEGIFN was permanently discontinued.
Trial: NCT02857530
Drug: rhTPO
RxNorm normalized name: rhTPO
DrugBank: Recombinant Human Thrombopoietin (DB16364)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhTPO
Trial: NCT00895128
Drug: Erlotinib Hydrochloride
RxNorm normalized name: Erlotinib Hydrochloride
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Starting dose of 100 mg taken by mouth 1 time a day every day for 28 day cycle or 50 mg for pediatric patients.
Trial: NCT00895128
Drug: Dasatinib
RxNorm normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Starting dose of 50 mg by mouth 1 or 2 times a day every day for 28 day cycle.
Trial: NCT00720512
Drug: irinotecan hydrochloride
RxNorm normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00720512
Drug: oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT03020875
Drug: Ofirmev
RxNorm normalized name: Ofirmev
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenously administered acetaminophen.
Trial: NCT00046852
Drug: carmustine
RxNorm normalized name: Carmustine
DrugBank: Carmustine (DB00262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00046852
Drug: melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00323778
Drug: Hyalgan
RxNorm normalized name: Hyalgan
DrugBank: Hyaluronic acid (DB08818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00721734
Drug: Carfilzomib
RxNorm normalized name: Carfilzomib
DrugBank: Carfilzomib (DB08889)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carfilzomib was administered intravenously (IV) at a rate of approximately 10 mL/minute.
Trial: NCT02525744
Drug: Insulin Lispro (Humalog)
RxNorm normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered SC
Trial: NCT00742872
Drug: Mosapride Citrate
RxNorm normalized name: mosapride citrate
DrugBank: Mosapride (DB11675)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One 5 mg tablet taken orally three times per day (15 min before meals) for 8 weeks.
Trial: NCT00466661
Drug: Acamprosate
RxNorm normalized name: Acamprosate
DrugBank: Acamprosate (DB00659)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 666 mg po TID
Trial: NCT04346901
Drug: Thiamazol
RxNorm normalized name: Thiamazol
DrugBank: Methimazole (DB00763)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All new hyperthyroid with melasma patients were recruited and their mMASI were calculated All subjects were given thiamazole by Internist based on their clinical hyperthyroidism After 3 months of taking hyperthyroid drugs (thiamazole), mMASI were recalculated and compared
Trial: NCT01070667
Drug: Dronedarone
RxNorm normalized name: Dronedarone
DrugBank: Dronedarone (DB04855)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 400mg orally once per day for 3 months
Trial: NCT00834639
Drug: divalproex sodium
RxNorm normalized name: Divalproex Sodium
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: delayed-release 500 mg tablet
Trial: NCT00226668
Drug: hCRF
RxNorm normalized name: hCRF
DrugBank: Corticorelin (DB05394)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hCRF 2mg/day; dexamethasone 4mg/day along with any open-label dexamethasone they may be taking
Trial: NCT03036384
Drug: HB Prilocaine 2% (varying dose)
DrugBank: Prilocaine (DB00750)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Varying dose of hyperbaric (HB) prilocaine 2% according to sensitive response of previous subjects. The dose of hyperbaric prilocaine 2% will be administrated intrathecally with 100µg of morphine and 2.5µg of sufentanyl
Trial: NCT03036384
Drug: HB Prilocaine 2%
DrugBank: Prilocaine (DB00750)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The dose of 45mg of hyperbaric (HB) prilocaine 2% will be administrated intrathecally with 100µg of morphine and 2.5µg of sufentanyl
Trial: NCT03036384
Drug: Morphine
RxNorm normalized name: Morphine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 µg Morphine
Trial: NCT06221423
Drug: Fruquintinib Combined With TAS-102
RxNorm normalized name: TAS-102
DrugBank: TAS-102 (DB08937)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fruquintinib Combined With TAS-102
Trial: NCT00794638
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The administration of rituximab 375 mg/m2 on Day 1 of each cycle will be followed by 18 days of observation. In the absence of adverse events or progressive disease, treatment will be repeated up to a maximum of 6 cycles, where 1 cycle is the 21-day treatment period (3 days of administration and 18 days of observation).
Trial: NCT04086212
Drug: Icodextrin, xylitol and carnitine solution for peritoneal dialysis
DrugBank: Icodextrin (DB00702)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive a long dwell exchange for three days.
Trial: NCT03264781
Drug: Cyclofem
RxNorm normalized name: ethinyl estradiol
DrugBank: Cyclo(his-pro) (DB02414)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscularly injection 0.5 ml of Cyclofem or placebo
Trial: NCT00725608
Drug: buprenorphine/naloxone
RxNorm normalized name: BUPRENORPHINE/NALOXONE
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 2/0.5 mg buprenorphine/naloxone and 8/2 mg buprenorphine/naloxone sublingual tablets; dosage and frequency are subject specific; subjects will receive treatment for up to 12 months
Trial: NCT02723903
Drug: Prozac
RxNorm normalized name: PROzac
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: we use Prozac for the patient with depression
Trial: NCT04243954
Drug: PCA IV Hydromorphone (continuous dose = 0)
RxNorm normalized name: lauryl PCA
DrugBank: Hydromorphone (DB00327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous PCA with hydromorphone after successful titration of 24 hours. the PCA setting: 1) continuous dose = 0; 2) bolus dose = 10-20% of the total dosage of hydromorphone in the previous 24 hours: 3) lockout time = 10 minutes; 4) evaluate once every 24 hours
Trial: NCT04243954
Drug: PCA IV Hydromorphone (continuous dose ≠ 0)
RxNorm normalized name: lauryl PCA
DrugBank: Hydromorphone (DB00327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous PCA with hydromorphone after successful titration of 24 hours. the PCA setting: 1) continuous dose (dose/hours) = the total dosage of hydromorphone in the previous 24 hours/24; 2) bolus dose = 10-20% of the total dosage of hydromorphone in the previous 24 hours; 3) lockout time = 10 minutes; 4) evaluate once every 24 hours
Trial: NCT04243954
Drug: Oral morphine
RxNorm normalized name: morphine Oral Tablet
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Swift to sustained-release morphine orally as background dose with immediate release morphine orally for breakthrough pain after successful titration of 24 hours.~Administration of morphine orally 1) Sustained-release morphine orally (dose/12 hours) = the total equianalgesic of the previous 24 hours/2×75% for d1; the total equianalgesic of the previous 24 hours/2 for day 2 and day 3; 2) Immediate release morphine orally = 10-20% of the total equianalgesic of the previous 24 hours; 3) Evaluate once every 24 hours
Trial: NCT00463762
Drug: CP-75385-02 Cefoperazone/sulbactam
DrugBank: Cefoperazone (DB01329)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04558567
Drug: Vogelxo
RxNorm normalized name: Vogelxo
DrugBank: Testosterone (DB00624)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50mg (1 tube, 5g gel) to 100mg (2 tubes, 10g gel)
Trial: NCT02573558
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02573558
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03409107
Drug: Daprodustat (GSK1278863)
RxNorm normalized name: daprodustat
DrugBank: Daprodustat (DB11682)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Daprodustat will be available as 9 millimeter (mm) or 7 mm film-coated tablets. Daprodustat will be administered once daily via oral route and can be taken without regard to food.
Trial: NCT02545361
Drug: KAHR-102
RxNorm normalized name: KAHR-102
DrugBank: KAHR-102 (DB17427)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KAHR-102 is a dual signaling protein (DSP).KAHR-102 will be administrated subcutaneously. In Stage 1A, 3 KAHR-102 SC injections will continue to be given every 14 days with an interval of 28 days after 1st cycle and 14 days after 2nd cycle and following cycles.~In Stage 1B and Stage 2, subjects will be administered 3 KAHR-102 SC injections given every 7 days with an interval of 28 days after 1st cycle and 14 days after 2nd cycle and following cycles.~Planned doses for stage 1:~Cohort A: 2µg/kg Cohort B: 4 µg/kg Cohort C: 8 µg/kg Cohort D: 12 µg/kg Each cohort will only begin its first administration of KAHR-102 SC injection when the cohort preceding it will not meet criteria for a DLT (at least 7 days).
Trial: NCT01176695
Drug: fish oil containing lipid emulsion
RxNorm normalized name: propofol lipid emulsion
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: medium chain triglycerides, long chain triglycerides, omega-3 fatty acid containing triglycerides
Trial: NCT01968707
Drug: ChloraPrep Hi-Lite Orange
RxNorm normalized name: ChloraPrep
DrugBank: Orange (DB10549)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apply topically.
Trial: NCT03620474
Drug: PRI-724
RxNorm normalized name: PRI-724
DrugBank: PRI-724 (DB15034)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: twice a week for 4 hours continuous intravenous administration of PRI-724